Beta cells of diabetes patients are dysfunctional – lacking the ability to respond to physiologic changes in glucose: They are “lazy”, but viable and retain the ability to produce insulin once revived. Abarceo Pharma has identified a novel diabetes target and has elucidated the key to the revival of dysfunctional beta cells enabling a resetting of the beta cell to a functional and healthy state. Upon treatment, dysfunctional “lazy” beta cells are revived and able to respond to physiologic changes in blood glucose producing insulin naturally. This represents the first potential disease-modifying treatment for type-2 diabetes which addresses the disease at the root and allows for durable and sustained glycemic control – by altering the natural history of the disease.